Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028?
Health & MedicineOne-Off2a
Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actual
No 66.2%
Pronosticadores
4
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 10 horas
Desactualizado16 ago 24, 0:43 UTC1 ene 29, 7:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2028?
Manifold MarketsWill there be an FDA Approved treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by 2030.
Manifold MarketsWill Retatrutide (new obesity drug) be FDA approved by the end of 2026?
Manifold MarketsOrion (a device that promises to project artificial vision into the brains of blind people) approved for sale by the end of 2027?
FutuurRaniPill microneedle pill to replace injections: approved for sale by the end of 2026?
FutuurTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurReglas
Glioblastoma (GBM) is a malignant brain tumor which has an overall survival average of >2 years.
- Current FDA approved treatments which positively impact survival include surgical resection, temozolomide chemotherapy, radiation, and tumor treating fields (TTF).
- The most recent approval which would qualify was a TTF device called Optune, which was approved in 2015.
- For this market to resolve YES, the drug(s) or device must be novel — drug repurposing doesn’t count unless the delivery system is truly novel.
- Surgical and radiological advancements generally will not count: however, surgically implantable devices which are novel and confer a survival benefit do count.
- Market will resolve YES even if the novel treatment is only approved to treat a subset of GBM patients.
Mercados abiertos
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 18,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volumen total
- 1,6 M €
- Volumen 24h
- 5,2 mil €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 resultados más
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volumen total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volumen total
- 916 mil €
- Volumen 24h
- 1,5 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 resultados más
- Volumen total
- 863,6 mil €
- Volumen 24h
- 1 mil €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028??
- Manifold Markets cotiza No al 66% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028??
- Está previsto que Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028? se resuelva el 1 de enero de 2029.
- ¿Cómo se liquida Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028??
- Manifold Markets liquida este mercado del siguiente modo: Glioblastoma (GBM) is a malignant brain tumor which has an overall survival average of >2 years.